Psoriasis: secukinumab tops ustekinumab in year-long CLARITY follow-up

  • Bagel J & al.
  • J Eur Acad Dermatol Venereol
  • 04/05/2020

  • Brian Richardson, PhD
  • Clinical Essentials
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • Secukinumab is associated with improved skin clearance and QoL compared with ustekinumab for patients with moderate to severe plaque psoriasis, according to 52-week follow-up of the phase 3b CLARITY trial.

Why this matters

  • This long-term analysis supports previous head-to-head data.

Key results

  • At week 52, secukinumab was associated with superior efficacy compared with ustekinumab:
    • Higher rate of ≥90% improvement in:
      • Psoriasis Area and Severity Index (PASI-90):
        • 73.2% vs 59.8%.
        • OR, 1.84 (P<.0001>
      • PASI-75:
        • 89.0% vs 82.1%.
        • OR, 1.74 (P=.0013). 
      • PASI-100:
        • 48.9% vs 33.5%.
        • OR, 1.92 (P<.0001>
    • A higher rate of Investigator’s Global Assessment modified 2011 responses of clear (0) or almost clear (1):
      • 76.0% vs 60.2%.
      • OR, 2.12 (P<.0001>
    • A higher rate of Dermatology Life Quality Index response of no effect (0/1):
      • 69.9% vs 61.2% (P=.0028).
    • Rates of adverse events were similar between patients treated with secukinumab and those treated with ustekinumab (68.5% vs 70.7%).

Study design

  • 1102 patients with moderate to severe plaque psoriasis were randomly assigned to secukinumab 300 mg (n=550) or ustekinumab 45/90 mg (n=552) and analyzed for efficacy and safety outcomes after 52 weeks.
  • Funding: Novartis Pharma AG.

Limitations

  • Lack of predefined statistical threshold for superiority of exploratory endpoints.